# HIKMA: manufacturing (CMC) supplement approved for FUROSEMIDE

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | HIKMA |
| Product | FUROSEMIDE |
| Generic / ingredient | FUROSEMIDE |
| Approval | Drug manufacturing (CMC) supplement |
| Application | ANDA070433 supplement 38 |
| Decided | 2026-10-16 |
| Panel / class | SOLUTION, ORAL |

## Why this score
- Decided in the last 30 days.
- Manufacturing change: sites, suppliers or process.

Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070433). Last refreshed: 2026-11-05T08:47:15.055Z.
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.